Beijing Kang'erfu Pharmaceutical

Beijing Kang'erfu Pharmaceutical is a high-tech pharmaceutical company based in Beijing, China, specializing in the research, development, and manufacturing of modern Traditional Chinese Medicine (TCM) and chemical drugs. Founded in 1992 and operating as a key subsidiary of the Kangerfu Holding Group, the company maintains a significant manufacturing presence in the Zhongguancun Science Park with multiple GMP-certified production lines. Its flagship product, Icaritin (Akelading), is a first-in-class TCM-derived small molecule approved for the treatment of unresectable hepatocellular carcinoma. The company's portfolio also includes proprietary treatments such as Naoxuekang Dropping Pills for intracerebral hemorrhage and various therapies for renal and respiratory health. By integrating traditional herbal knowledge with modern pharmacological standards, Beijing Kang'erfu Pharmaceutical aims to address critical unmet needs in oncology and cardiovascular medicine. The company is recognized as a Specialized and Sophisticated enterprise in Beijing, reflecting its commitment to innovation and quality in the Chinese pharmaceutical industry.